Vitae Pharmaceuticals (NASDAQ: VTAE) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitabiliy, earnings and dividends.
Risk and Volatility
Vitae Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 5.15, indicating that its share price is 415% more volatile than the S&P 500.
Earnings & Valuation
This table compares Vitae Pharmaceuticals and Syndax Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Syndax Pharmaceuticals||$1.22 million||200.95||-$48.05 million||($2.61)||-5.15|
Vitae Pharmaceuticals has higher revenue, but lower earnings than Syndax Pharmaceuticals. Vitae Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for Vitae Pharmaceuticals and Syndax Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vitae Pharmaceuticals currently has a consensus target price of $21.67, suggesting a potential upside of 3.17%. Syndax Pharmaceuticals has a consensus target price of $26.17, suggesting a potential upside of 94.84%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Vitae Pharmaceuticals.
This table compares Vitae Pharmaceuticals and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
72.6% of Vitae Pharmaceuticals shares are held by institutional investors. Comparatively, 53.5% of Syndax Pharmaceuticals shares are held by institutional investors. 14.8% of Vitae Pharmaceuticals shares are held by insiders. Comparatively, 24.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Syndax Pharmaceuticals beats Vitae Pharmaceuticals on 9 of the 11 factors compared between the two stocks.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer’s disease, or Alzheimer’s. VTP-43742, the Company’s wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.